scout

Authors

David Parker, PhD
Latest Article

CMS Decision Helps Unlock the Potential of Next-Generation Testing

Provisions to a final national coverage determination that expanded coverage for next-generation sequencing tests have implications for any NGS-based cancer test provided to Medicare beneficiaries and will inevitably influence the coverage thinking of commercial payers.

David Planchard is a thoracic oncologist and head of the thoracic pathology committee at Gustave Roussy. He is also president of the International Center for Thoracic Cancers (CICT), a health cooperation group combining Gustave Roussy, the Marie-Lannelongue Hospital, and the Paris Saint-Joseph Hospital.
David Planchard, MD, PhD

David Planchard is a thoracic oncologist and head of the thoracic pathology committee at Gustave Roussy. He is also president of the International Center for Thoracic Cancers (CICT), a health cooperation group combining Gustave Roussy, the Marie-Lannelongue Hospital, and the Paris Saint-Joseph Hospital.

David R. Gandara, MD, UC Davis
David R. Gandara, MD, UC Davis Comprehensive Cancer Center
David S. Hong, MD, MD Anderson Cancer Center
David S. Snyder, MD, FACP, City of Hope
David Spigel, MD, Sarah Cannon Research Institute
David Tom Cooke, MD, FCCP, FACS
Latest Article

MEDCAC Ruling on Lung Cancer Screening

The MEDCAC ruling will likely lead to non-coverage of lung cancer screening with low dose CT scans for Medicare and Medicaid beneficiaries.

David Wheeler, CPA, MBA
Latest Article

Dipping a Toe Into Care Management

Fee-for-service remains the primary driver of patient revenue for the majority of oncology practices across the country, and the same is true for The Center for Cancer and Blood Disorders.

Dawn Dolan, PharmD, BCOP, Moffitt Cancer Center
Dean F. Bajorin, MD, Memorial Sloan Kettering Cancer Center
Dean F. Bajorin, MD, MSKCC
Latest Article

Making an Impact in the Fight Against GU Cancers as Scientist, Physician, and Teacher

Long before Dean F. Bajorin, MD, would travel the world as a renowned expert in genitourinary cancers—presenting at international conferences, working with major task forces, and changing the paradigms of care for patients in every corner of the globe—he began with a decidedly shorter journey: to college.

Deborah Abrams Kaplan
Latest Article

Addressing AYA Cancer Requires a Tailored Approach to Practice

Investigators have expanded the scientific understanding of cancer in the adolescent young adult patient population over the past decade. However, unmet needs remain in establishing treatment standards, addressing unique survivorship challenges, and providing a framework for patients to reference as they navigate their cancer journey.

Debra Patt, MD, MPH, MBA
Latest Article

Federal Indecisiveness Belies Significant Changes in Medicaid Policy State by State

Today’s healthcare landscape is rapidly evolving, with many trends emerging and policy changes under consideration that have far-reaching implications for cancer care.

Debra Wood
Latest Article

Mayo Study Characterizes Pembrolizumab-Induced Thyroiditis

Abnormal thyroid function tests were reported in up to 15% of patients treated with the PD-1 inhibitor pembrolizumab.

Debu Tripathy, MD, University of Texas MD Anderson Cancer Center
Deepika Narasimha, MD1, Anthony Jarkowski, III, PharmD2,and Nikhil I. Khushalani*, MD1,3
Delshad Ahmad, MD
Latest Article

Hemophagocytic Lymphohistiocytosis in a Patient With Nodular Lymphocyte–Predominant Hodgkin Lymphoma: A Case Report

This is the first case report of hemophagocytic lymphohistiocytosis complicating a nodular lymphocyte–predominant Hodgkin lymphoma in an adult treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.

Deni Deasy Boekell
Latest Article

The Evolving Use of White Bagging in Oncology

Channel dynamics are changing for physician-administered infusible drugs, with implications for practice economics, payer utilization management, site of care, and availability of data for manufacturers.

Denise A. Yardley, MD, Sarah Cannon
Denise A. Yardley, MD, Sarah Cannon Research Institute
Denise Myshko, OncLive
Denise Myshko

Senior Editor, OncLive®
Denise Myshko is your editorial contact for the Oncology Business Management section of OncologyLive, as well as the corporate newsletters. She joined OncologyLive in March 2020. Before that, she was managing editor of PharmaVOICE, a trade publication in the pharmaceutical industry. Email: dmyshko@onclive.com

Latest Article

No-Cost Counseling Can Address Psychosocial Needs of Patients With Cancer

Counseling, psychotherapy, and mental health services provide the opportunity to develop coping skills and inspire hope; however, patients often experience hurdles to accessing such care. Among these obstacles are cost, unawareness that programs exist, the COVID-19 pandemic, and other external factors.

Denise Soltow Hershey, PhD, RN, FNP-BC
Latest Article

Improving Glycemic Control in Individuals With Cancer and Diabetes

It is estimated that 8%-18% of all cancer patients will have preexisting diabetes at the time they are diagnosed with cancer.

Dennie V. Jones, Jr, M
Latest Article

Hedgehog Signal Inhibition Hope or Hype?

Once a human malignancy metastasizes, currently available cytotoxic chemotherapy is usually palliative. While conventional chemotherapy regimens are associated with objective tumor regression, this only occurs in a minority of patients.

Dennis Bittner, PhD
Latest Article

Liquid Biopsy Technology Grows More Varied and Potentially More Useful in NSCLC

The definition of liquid biopsy has expanded to include the collection of cell-free DNA (cfDNA), along with various species of cell-free RNA and exosomes, all of which are capable of providing information on the disease status of patients with cancer.

Dennis C. Shrieve, MD, PhD
Latest Article

The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment Recommendations

Researchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.

Dennis D. Hickstein, MD
Latest Article

Primary Radiation Therapy for Myeloid Sarcoma of the Porta Hepatis

Treating myeloid sarcoma at the porta hepatis with 24 Gy over 12 fractions is a well-tolerated treatment that achieved a complete, durable response with minimal toxicity.

denosumab-wins-drug-award
Latest Article

Denosumab Wins Drug Award

At the 6th Annual Scrip Awards, featuring more than 500 representatives from the pharmaceutical industry, Amgen received the Best New Drug award for denosumab, the first approved inhibitor of RANK ligand.

Deukwoo Kwon, PhD
Latest Article

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

Devalingam Mahalingam, MD, PhD
Latest Article

Autophagy Modulation May Be a Novel Approach to Treatment of Advanced Cancers

Although prolonged autophagy can result in cancer cell death, recent investigations suggest that therapy-induced autophagy is a reversible response that promotes cancer cell survival, and thus may diminish the efficacy of some therapeutic agents.